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Background: Recent evidence proposes a novel concept that mammalian natural antisense RNAs play important
roles in cellular homeostasis by regulating the expression of several genes. Identification and characterization of
retroviral antisense RNA would provide new insights into mechanisms of replication and pathogenesis. HIV-1
encoded-antisense RNAs have been reported, although their structures and functions remain to be studied. We
have tried to identify and characterize antisense RNAs of HIV-1 and their function in viral infection.
Results: Characterization of transcripts of HEK293T cells that were transiently transfected with an expression
plasmid with HIV-1NL4–3 DNA in the antisense orientation showed that various antisense transcripts can be
expressed. By screening and characterizing antisense RNAs in HIV-1NL4–3-infected cells, we defined the primary
structure of a major form of HIV-1 antisense RNAs, which corresponds to a variant of previously reported ASP
mRNA. This 2.6 kb RNA was transcribed from the U3 region of the 3′ LTR and terminated at the env region in
acutely or chronically infected cell lines and acutely infected human peripheral blood mononuclear cells. Reporter
assays clearly demonstrated that the HIV-1 LTR harbours promoter activity in the reverse orientation. Mutation
analyses suggested the involvement of NF-κΒ binding sites in the regulation of antisense transcription. The
antisense RNA was localized in the nuclei of the infected cells. The expression of this antisense RNA suppressed
HIV-1 replication for more than one month. Furthermore, the specific knockdown of this antisense RNA enhanced
HIV-1 gene expression and replication.
Conclusions: The results of the present study identified an accurate structure of the major form of antisense RNAs
expressed from the HIV-1NL4–3 provirus and demonstrated its nuclear localization. Functional studies collectively
demonstrated a new role of the antisense RNA in viral replication. Thus, we suggest a novel viral mechanism that
self-limits HIV-1 replication and provides new insight into the viral life cycle.Background
The genome of HIV-1 is about 9 kb with complex patho-
genic mechanisms. HIV-1 encodes nine viral proteins,
which have multiple functions in molecular events such as
entry, integration, and viral gene expression, as well as the
regulation of host molecular processes [1-3]. However,
there still remain unanswered questions about the
mechanisms of HIV-1 infection and pathogenesis despite
advances in the knowledge of many diverse viral functions.
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distribution, and reproduction in any mediumreactivation have not been fully elucidated, and several
events have been suggested to be involved in viral latency,
including epigenetic reprogramming and modulated
expressions of host factors [4-6].
Several researchers have embarked on studies to identify
HIV-1 antisense RNAs (asRNAs) [7-11]. Using computa-
tional analysis, Miller predicted the existence of a novel
gene in the antisense strand of HIV-1, which encodes ASP
by a well-conserved open reading frame among many
strains of HIV-1 [7]. Subsequently, the ASP mRNA was
identified as a 2242 bp transcript covering the region
between nucleotide positions 9608 and 7367 of the HXB2
strain in acutely infected A3.01 cells [8]. However, the
primary structure and functions of HIV-1 asRNAs have noted Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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posed the potential importance of the asRNAs [9,12-20].
Other retroviral asRNAs have also been studied. In
HTLV-1-infected T-cells, the HBZ RNA is expressed from
the antisense strand of the HTLV-1 provirus. HBZ has been
reported to be involved in the regulation of sense transcrip-
tion and leukemogenesis by HTLV-1 [21-26]. Furthermore,
feline immunodeficiency virus and Friend and Moloney
murine leukemia virus have also been suggested to express
antisense transcripts [27,28]. In addition, Ty1 retrotrans-
poson was shown to express three types of asRNAs, which
can regulate the Ty1 copy numbers in yeasts [29].
Recent studies including the FANTOM3 mouse
transcriptome sequencing consortium identified natural
antisense transcripts for more than 70% of transcription
units (TUs), most of which represent non-protein-coding
RNAs [30,31]. The existence and functional importance
of asRNAs in various species have also been
elucidated [31-34]. Various natural antisense RNAs
(NATs) play important roles in the regulation of gene
expression through diverse molecular mechanisms,
such as X-chromosome inactivation (Tsix), genomic
imprinting (Air), and trans-acting regulation (HOTAIR
and ANRIL) of its sense strand expression [31,35-40].
Furthermore, abnormal expression of asRNAs is reported
to be one of the risk factors in some diseases such as α-
thalassemia, cardiac diseases, and Alzheimer’s disease
[37,41,42]. Thus, the transcriptional control of asRNAs is
considered to be a potential target for the development of
new treatment strategies as well as the prevention of
diseases.
Consequently, the identification and delineation of the
precise primary structure and functions of HIV-1 asRNAs
is urgently needed, because that information may provide
new insights into the pathogenic mechanisms of HIV-1. In
the present study, we identified an apparent major form of
asRNAs, ASP-L, in HIV-1NL4-3 and HIVIIIB infected cells.
The results demonstrated that the ASP-L is localized in the
nucleus and has a potential to negatively regulate HIV-1
replication. These findings suggest a novel mechanism that
may play a role in the self-limiting replication of HIV-1.
Results
Mapping of potential antisense RNAs from HIV-1 proviral
DNA
Specific detection and identification of antisense transcripts
of HIV-1 is difficult because of the presence of several sense
transcripts [8,11]. Thus, we first attempted to characterize
the candidate transcripts from the antisense strand of HIV
DNA. We studied the transcripts in HEK293T cells that
were transiently transfected with an expression plasmid,
pME18S-asHIV, which contains the gag to nef region of
HIV-1NL4–3 DNA in the antisense orientation was posi-
tioned between the RSV promoter and the SV40 poly (A)sites (Figure 1A). Total RNAs were extracted from the
transfected cells and comprehensively analyzed by
Northern blots using region specific probes against the
HIV-1 p1–p5 regions (Figure 1B). Four major bands were
detected that may represent potential antisense transcripts
as shown in Figure 1B. We named these four bands I to IV
based on their apparent molecular sizes. Transcript I is
apparently a 10 kb genome-length transcript, and transcript
II is a 5.5 kb transcript detected by p2–p5 probes.
Transcript III appears to be a group of transcripts of 3–
4 kb in size that hybridized with all probes except the p1
probe. Transcript IV is a 2 kb transcript that hybridized
with p3, p4, and p5 probes, with a stronger signal to the p5
probe. Taken together, the results indicate that various
transcripts can be transcribed from the antisense strand of
HIV-1 DNA. Among these transcripts, those grouped in
transcript III are expressed at high levels.
To characterize the detailed structure of these transcripts,
we next performed RT-PCR analyses and 3′ RACE PCRs,
and determined the spliced sites and the transcription ter-
mination sites (Additional file 1: Figure S1and Additional
file 2: Figure S2). Nucleotide sequence analyses of the
amplified products revealed three kinds of spliced
transcripts and four polyadenylation sites, suggesting seven
kinds of potential asRNAs (Figure 1C). They are described
as follow: Transcript I, a transcript with genome-length;
Transcript II, a 5.5 kb transcript covering the nucleotide se-
quence from 9102 to 4885 of HIV-1NL4–3-sense DNA
[GenBank: M19921.2] which corresponds to ASP mRNA
reported by Landry et al. [11]; Transcripts III-i and III-ii,
4 kb transcripts terminating at the SV40 poly(A) sites in
the vector; Transcript III-iii, a 3 kb transcript ranging from
the nef to env regions of the sense strand (See Additional
file 1: Figure S1. Determination of transcript III-iii); and
Transcript IV, two transcripts terminating at the SV40 poly
(A) sites (transcript IV-i) or at 7338 bp (transcript IV-ii)
which corresponds to ASP mRNA reported by Michael
et al. [8].
Detection of HIV-1 antisense RNAs in infected cells
Based on the above results, we next examined whether the
putative asRNAs are expressed in HIV-1-infected cells.
Previous reports have documented that endogenous prim-
ing in the step of cDNA synthesis prevents strand-specific
RT-PCR for analysis of intragenic asRNAs [11,43]. To
eliminate the nonspecific amplification products, we uti-
lized the strand-specific RT-PCR method (Figure 2A)
[11,23], using MAGIC-5A cells infected with HIV-1 [44].
Antisense-specific RT-PCR was performed on five regions,
R1–R5. Viral asRNAs were detected in all regions analyzed
in MAGIC-5A infected with HIV-1NL4–3 (Figure 2B). How-
ever, no cDNA was amplified that corresponds to a spliced
form of asRNA, including transcripts III-i, III-ii, and IV-i
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Figure 1 Mapping of the potential antisense RNAs transcribed from the HIV-1 proviral DNA. (A) A schematic diagram of the pME18S-
asHIV plasmid. The antisense strand of HIV-1NL4–3 DNA was inserted downstream of the SRα promoter. (B) Results of Northern blot analysis for
the detection of the RNAs from pME18S-asHIV. HEK293T cells were transfected with pME18S-asHIV or a mock vector, pME18S. Total RNA samples
isolated from these cells were analyzed with region-specific probes described in A (p1–p5). GAPDH RNA was used as a loading control. The
arrows described below are the positions of potential transcripts I–IV as described in the results. ‘Mock’ stands for the RNA sample extracted from
cells transfected with a mock vector. ‘As’ stands for RNA samples extracted from cells transfected with pME18S-asHIV. (C) The summary of the
transcription patterns in pME18S-asHIV-transfected cells. Spliced variants derived from antisense HIV-1 were identified by RT-PCR, and termination
sites were determined by the 3′ RACE methods described in Additional file 1: Figure S1 and Additional file 2: Figure S2. Nucleotide numbering
corresponds to the sense strand of HIV-1NL4–3-DNA.
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and 9094 bp and are unspliced forms in HIV-1 infected
cells.
Identification of a novel variant of ASP RNA, ASP-L
The above results suggested that asRNAs of HIV-1, in-
cluding transcripts I, II, III-iii and IV-ii, can be expressed
in HIV-1-infected cells. To confirm the existence of thesepotential asRNAs and determine their primary structures,
we next studied HIV-1 asRNAs in HIV-1-infected
MAGIC-5A by 3′ RACE PCR analyses. Using the primer
p4R that is located in the ASP open reading frame (ORF),
a PCR product with an apparent molecular size of 700 bp
was amplified in the infected MAGIC-5A cells (Figure 3A
and B, lane 2 in the upper panel). In contrast to these
results, no PCR products were amplified from the infected






















Figure 2 Antisense-specific RT-PCR of HIV-1 RNA. (A) A diagram
describing the strand-specific RT-PCR method for HIV-1 asRNA. RNA
samples were reverse-transcribed by an antisense-specific primer with
a 5′ tag sequence (Tag-RT-primer). The synthesized cDNA samples
were then amplified by PCR with a primer corresponding to the tag
sequence (Tag primer) and a primer complementary to the target
cDNA (PCR primer). (B) Detection of asRNAs in MAGIC-5A cells infected
with HIV-1NL4-3. The top panel describes the position of R1–R5 region.
Lower panels show the results of agarose gel electrophoresis of
products of the antisense-specific RT-PCR targeting R1–R5 regions. PCR
products were detected corresponding to all 5 regions studied. Lane 1,
MAGIC-5A without virus; Lane 2, MAGIC-5A with HIV-1NL4-3; Lane 3, no
RTase control; Lane 4, no RT primer control (a control for endogenous
priming); Lane 5, PCR products with conventional primer pairs with
cDNA samples synthesized by random primers (for testing sense and
antisense RNA expressions); Lane 6, positive control (amplified from
pNL4-3 plasmid DNA).
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in the lower panel).
Semi-nested PCR using the PCR product by 3′ RACE
with p4R primer produced one major product and one
minor product, about 500 and 600 bp in size, in the
infected MAGIC-5A cells. Analysis of the nucleotide
sequences of these PCR products revealed a major poly (A)
addition site that is located at the nucleotide position 6878
and other minor ones. Among the minor ones, one that
extends to the nucleotide position 6783 corresponds to the
larger PCR product. Thus, the results collectively showed
that two groups of HIV-1 asRNAs were polyadenylated at
nucleotide position 6878 (the major one) and 6783 (the
minor one) in the env region (Figure 3C), which
corresponds to the region of transcript III-iii (Figure 1C). Insilico prediction identified a polyadenylation signal at
nucleotide positions 6909 to 6918, which seems to be
involved in the termination of the asRNA (Figure 3C).
Next, we studied the initiation site of the asRNA by using
two reverse primers (9418r and 9538r). Antisense-specific
RT-PCR with the primer 9418r successfully amplified a
cDNA, whereas that with 9538r primer did not (Figure 3D).
These results suggested that the transcriptional start site
(TSS) is located between 9418 and 9538 of the proviral
DNA. We next performed 5′ RACE to determine the TSS
of the antisense transcript in the infected MAGIC-5A. The
results indicated that the main TSS is at 9451 (Figure 3E), a
finding supported by the successful amplification of cDNA
by antisense-specific RT-PCR targeting the region between
nucleotide positions of 6878 and 9451 (data not shown). In
silico analysis predicted that this asRNA contains a few
ORFs, of the previously reported ASP mRNA [8] and an
extended 3′ UTR of approximately 500 bases compared
with that of ASP mRNA (Figure 3A). The RT-PCR results
suggested that this asRNA was mainly detected in infected
MAGIC-5A cells (See Additional file 3: Figure S3).
Taken together, we have identified two new forms of
asRNAs that are transcribed from the nucleotide position
9451 in the 3′ LTR U3 region of HIV DNA and termi-
nated at nucleotide position 6878 or 6783 in the env
region. We named these variants “ASP RNA-Long variant”
(ASP-L)[GenBank: JQ866626]; a major variant terminated
at 6878 is named as “ASP-L1,” and a minor variant termi-
nated at 6783 as “ASP-L2.”Transcriptional activity of the LTR in the antisense
orientation
Since the transcription start sites (TSSs) of the newly
characterized HIV-1 asRNAs are in the U3 region of 3′
LTR, the R-U5 region is expected to have antisense pro-
moter activity. To study the promoter activity, we first
performed a computational analysis of this region. The
results revealed a potential TATA box at the nucleotide
position −48 to −54 from the TSS as well as a couple of
potential motifs that are recognized by transcription fac-
tors, such as CdxA, Nkx-2, and AP-1 (Figure 4A). To ex-
perimentally verify the promoter activity of this region, we
performed luciferase reporter assays in Molt-4 cells using
three kinds of constructs that have varying lengths of U3-
R-U5 region (300 bp to140bp) in the antisense orientation
(pGL4-asLTR-1, pGL4-asLTR-2, and pGL4-asLTR-3)
(Figure 4A). Transfection of pGL4-asLTR-1 demonstrated a
luciferase activity, the level of which was approximately
one-third of that of the sense orientation LTR (pGL4-5′
LTR) (Figure 4B). Luciferase reporters having shorter
regions (pGL4-asLTR-2 and pGL4-asLTR-3) also showed
similar levels of promoter activities. On the other hand, a
control construct that had a DNA fragment of the env
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6950 gtactgtgct gacatttgta catggtcctg 6921  
6920 ttCCATTGAA CGtcttatta ttacatttta 6891 
6890 gaatcgcaaa acCaGCcggg gcacaataat 6861  
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Figure 3 Identification of an antisense RNA from HIV-1-infected cells. (A) A schematic representation of the HIV-1 asRNAs and primers for 3'
RACE. The black arrow represents the ASP-L transcript characterized in this study, and dotted arrows are the ASP mRNAs as previously described [8,14].
The bold green arrow indicates the position of the potential ORF, ASP. (B and C) Results of 3' RACE. ‘MAGIC5A-HIV’ stands for HIV-1 infected MAGIC-5A
and ‘293 T-asHIV’ for HEK293T cells transfected with pME18S-asHIV. Lane 1 and 5, no infection control or mock transfected cells; Lane 2 and 6, cells with
HIV-1 infection or transfected with pME18S-asHIV; Lane 3 and 7, no RTase control; Lane 4 and 8, no RT-primer control; M, 100 bp marker. (B) The result
of 3′ RACE PCR using the p4R primer (upper panel) and the p3R primer (lower panel). The asterisk indicates the PCR product representing ASP-L. ‘II’, ‘III-iii’
and ‘IV-ii’ represent the PCR product derived from transcripts II, III-iii and IV-ii, respectively, described in Figure 1. (C) Upper panel: Results of semi-nested
PCR with the YT001 primer. The white asterisks represent ASP-L-variant forms; the upper asterisk indicates ASP-L2, the lower one ASP-L1. The yellow
asterisks represent transcript III-iii. Results of the sequencing analyses are shown in the bottom panel, where arrows and upper case letters indicate the
termination sites. The bold arrow, end of the major transcript; the blue upper letters, a putative polyadenylation signal predicted by HCpolya (see
Methods); the underline, putative polyadenylation elements of ASP-L. (D and E) Identification of transcription start site (TSS) of ASP-L. (D) Results of
antisense-specific RT-PCR with two kinds of reverse primers. Locations of p5Ftag (Tag-RT-primer), 9418r, and 9538r are described in E. Lanes 1–6 are the
same as in Figure 2B. (E) A schematic description of ASP-L RNA. The upper case letter C in the sequence indicates the position of ASP-L TSS.
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moter activity.
To study the regulation of promoter activity of the LTR in
the antisense orientation (asLTR), we next tested whether
the viral accessory protein, Tat, or a cellular cytokine, TNF-α
modulates the activity. Results of cotransfection experiments
with a Tat expression plasmid did not show any activation
of the antisense promoter, whereas the sense orientation
LTR (pGL4-5′ LTR) responded to Tat in a dose-dependentmanner, as expected (Figure 4C). On the other hand, TNF-α
activated pGL4-asLTR-1 in a dose-dependent manner as
was observed on the pGL4-5′ LTR (Figure 4D). TNF-α
treatment of ACH-2 activated the expression of both strands
(See Additional file 4: Figure S4).
The results shown in Figure 4D suggested the involve-
ment of NF-κB in the regulation of 3′ LTR promoter ac-
tivity in the antisense orientation. To examine this
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Figure 4 Transcriptional activity of the HIV-1 3' LTR in the reverse orientation. (A) A map of HIV-1 3' LTR and reporter plasmids. Top panel
shows results of promoter prediction of the 5'-flanking region of the ASP-L TSS by TFsearch and Genetyx. Green box indicates putative TATA box. The
sequence of the putative TATA box is described in F. The bottom panels are the structures of pGL4-asLTR-1, pGL4-asLTR-2 and pGL4-asLTR-3 plasmid. (B)
Promoter activities of the LTR in the antisense orientation (asLTR). pGL4-5' LTR and pGL4-asEnv plasmids were used as positive and negative controls,
respectively. mock, pGL-4.10; asEnv, pGL4-asEnv; asLTRs, pGL4-asLTR-1, pGL4-asLTR-2 and pGL4-asLTR-3; 5′ LTR, pGL4-5' LTR. The luciferase activities
relative to that of pGL4-5' LTR are shown. (C) Effects of Tat protein on the asLTR promoter activity. A Tat expression plasmid, pME18S-tat, was co-
transfected with pGL4-asLTR-1 or pGL4-5' LTR. (D) Dose–response effects of TNF-α on the asLTR promoter activity. At 12 h post-transfection of the
reporters, cells were treated with various amounts of TNF-α (0–10 ng/mL) for 12 h. (E-H) Investigation of transcriptional regulatory elements in the asLTR.
(E) A schematic description of series of asLTR mutant reporters. asLTR-ΔκB lacks two NF-κB binding sites. asLTR-TATA mut1 and mut2 contain mutated
TATA box. (F) Sequences of the potential TATA box mutants. (G) Promoter activities of the asLTR mutants. The luciferase activities relative to that of
pGL4-5' LTR are shown. (H) Effects of TNF-α on the ΔκΒ mutant. The experimental condition is identical to D. ‘delta kB’ stands for pGL4-sLTR-ΔκΒ. ‘wild
type’ stands for pGL4-asLTR-1. The mean ± S.D. of quadruplicate (B) or triplicate (C, D, G, and H) experiments are shown. The asterisks shown in C, D, G,
and H indicate statistical significance.
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motifs. The basal promoter activity of the asLTR-ΔκB was
significantly decreased compared with that of wild type
(Figure 4G) and lost responsiveness to TNF-α treatments
(Figure 4H). We further tested the possible involvement
of the putative TATA box using two kinds of mutant
reporters, pGL4-asLTR-TATA mut1 and pGL4-asLTR-
TATA mut2 (Figure 4E and F). pGL-4asLTR-TATA mut1
has a T to G point mutation at the potential TATA box,
which lacks a TATA activity [45,46]. pGL-asLTR-TATA
mut2 has mutations with a deletion of the TATA motif.
The results demonstrated no difference in the basal pro-
moter activity compared with that of wild type asLTR
(Figure 4G).
ASP-L expression in various types of cells infected with
HIV-1
To study the expression of HIV-1 asRNAs in various types
of HIV-1-infected cells, we analyzed RNA samples from
Molt-4 acutely infected with HIV-1NL4–3, as well as in
ACH-2, and OM10.1 cell lines that are chronically infected
with HIV-1IIIB [47,48] with the antisense-specific RT-PCR.
In this experiment, we designed an antisense-specific RT-
PCR with a Tag-RT-primer that does not amplify the ASP
mRNA reported by Michael et al. [8] (Figure 5A). The
asRNA expression was detected in all the cell lines
examined (Figure 5B). Furthermore, we could also detect
asRNA in the PHA-activated PBMCs infected with HIV-
1NL4–3 (Figure 5C). 3′ RACE analyses revealed similar
transcription termination in OM10.1 and activated ACH-
2 cells, where HIV-1IIB also had a conserved polyadenyla-
tion signal (Figure 5D). By antisense-specific RT-PCR ana-
lyses, we demonstrated that TSS of ASP-L from HIV-1IIB
was located between nucleotide positions 9441 and 9538
that correspond with that from HIVNL4–3 (Figure 5E). Col-
lectively, ASP-L was demonstrated to be transcribed in cell
lines with acute or chronic infection as well as in primary
human PBMCs infected with HIV-1.
To evaluate the expression levels of the asRNA in various
cells, quantitative analysis was performed using the strand-
specific quantitative RT-PCR method (qRT-PCR) of the R7
region (Figure 5A and 5F). The results showed that the
highest expression level was observed in OM10.1. The ex-
pression levels of HIV-1 asRNAs were shown to be 100–
2,500 times less abundant than those in the sense RNA
transcripts in all cells.
Sub-cellular localization of HIV-1 antisense RNAs
The subcellular localization of asRNAs could be a key to
understand the possible functions of asRNAs [30,38,49].
We, therefore, studied the localization ratios of HIV-1 asR-
NAs between the cytoplasm and nucleus. For this purpose,
HIV-1-infected MAGIC-5A and OM10.1 cells were fractio-
nated into the cytoplasmic and nuclear portions, followedby RNA extraction. The results of antisense strand-specific
RT-PCR at R8 region revealed that the majority of HIV-1
asRNAs was enriched in the nuclear fractions in both cell
lines, whereas the sense strand transcripts did not show
such a biased distribution (Figure 6A). To evaluate the dis-
tribution more quantitatively, we next employed qRT-PCR
at the R7 region. The results revealed that more than 77%
of the asRNA is located in the nuclei of various cells
including primary PHA-activated PBMC (Figure 6B–D).
This significantly biased nuclear localization was also con-
firmed in ACH-2 and HIV-1-infected Molt-4 (See
Additional file 5: Figure S5. Sub-cellular localization of
HIV-1 antisense RNAs in the HIV-1 infected T cell lines).
Taken together, these results indicate that ASP RNAs are
localized mainly in the nuclei of the acutely or chronically
infected cell lines as well as in the nuclei of primary PBMCs
newly infected by HIV-1.
Inhibitory effects of the antisense RNA on HIV-1
replication
To understand the function of HIV-1 asRNAs, we studied
the effects of ASP-L on HIV-1 replication. MAGIC-5A cells
were transiently transfected with an ASP-L expression
vector, pIRES-RSV-ASP-L, or a vacant vector, followed by
infection with HIV-1. At 48 h post-transfection (p.t.), the
levels of gag RNA decreased in ASP-L-expressing cells
compared to those in the control cells (Figure 7A). Semi-
quantitative PCR analysis of the genomic DNA did not
show any significant differences in the copy numbers of the
proviral DNA at p.t. 24 h, whereas it showed decreased
levels of proviral DNA in ASP-L-expressing cells at p.t. 48
and 72 h (Figure 7B). When the virus production was
evaluated by RT assays with the culture supernatants, it was
decreased in the ASP-L-expressing cells at p.t. 72 h with
statistical significance (p< 0.002) (Figure 7C).
To study the inhibitory effects of ASP-L on HIV-1 replica-
tion in T-cells, we prepared three clones of Molt-4 that sta-
bly express ASP-L (3C2, 3F1, and 3G9). After infecting these
cells with HIV-1, viral replication was evaluated by RT
assays. The results demonstrated a significant repression of
viral replication in the ASP-L-expressing cell lines for more
than 30 days post HIV-1 infection (dpi) (Figure 7D). qRT-
PCR analysis of the HIV-1 sense strand RNA did not show
any significant differences in the levels of gag and tat RNAs
at 1 dpi between the ASP-L-expressing cells and mock con-
trol cells; however, it demonstrated a 5-fold reductions in
the levels of gag and tat RNAs at 4 dpi in the ASP-L-expres-
sing cells compared to those levels in the control cells (Fig-
ure 7E and 7F). Semi-quantitative PCR of the genomic
DNA did not show a significant difference in the proviral
DNA levels between ASP-L-expressing and control cells at 1
dpi, whereas decreased levels of proviral DNA copies were
shown in ASP-L-expressing cells at 4 dpi (Figure 7G).
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Figure 5 Expression of the HIV-1 antisense RNA in various types of HIV-1-infected cells. (A) A schematic representation of positions of ASP-L
and ASP mRNA in the antisense strand of HIV-1NL4-3 genome. Arrows indicate the regions of the antisense-specific RT-PCR (R6, R7, R9, and R10). (B and
C) Results of antisense-specific RT-PCR at R6 region. Total RNAs from HIV-1NL4-3-newly infected Molt-4 and MAGIC-5A cells, and ACH-2 and OM10.1
chronically infected cell lines were analyzed by the antisense-specific RT-PCR (B). Results of HIV-1NL4-3 infected-PBMCs from three healthy individuals
(HIV-1-PHA-blast #1–#3) are shown in (C). Lane1, uninfected cell line or PBMC; Lane 2, HIV-1 infected cell line or PBMC; Lane 3, no RTase control; Lane
4, no RT primer control, Lane 5; amplified from cDNA synthesized with random primers; Lane 6, positive control (amplified from pNL4-3 plasmid DNA
or cellular genomic DNA). (D) Termination sites of HIVIIIB ASP-L. Summary of 3' RACE analyses in OM10.1 and TPA-stimulated ACH-2 is shown. The
upper letters mean transcription termination sites in black (ACH-2), green (OM10.1) and red (HIV-1NL4-3 infected MAGIC-5A cells). The black and green
arrows are the major transcript in ACH-2 and OM10.1, respectively. (E) Determination of ASP-L TSS in HIVIIIB. The results of antisense-specific RT-PCR at
R9 and R10 are shown. Lanes 1–6 are the same as in Figure 2B. (F) Relative expression levels of the antisense and sense transcripts. Results of the
strand-specific qRT-PCR at R7 region are shown to measure the expression levels of the antisense and sense transcripts (sense RNA). Expression levels
were normalized by the levels of β-actin gene expression. Results of triplicated experiments are shown with mean ± S.D.
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observed in clone 3C2 that expresses the highest levels of
ASP-L, where the level of ASP-L was estimated to be
about 120 times more abundant than that in OM10.1 (Fig-
ure 7F and H). Furthermore, the nuclear localization of
ASP-L in the ASP-L-expressing clones was confirmed as
described above (See Additional file 6: Figure S6. Sub-cel-
lular localization of ASP-L in Molt-4 stably expressing
ASP-L). Contrary to above results, the cells expressing the3′ region of ASP-L showed no inhibitory effect on HIV-1
replication (See Additional file 7: Figure S7A-C).
Upregulation of HIV-1 expression by knockdown of the
endogenous antisense RNA
As described above, the enforced expression of ASP-L
downregulated the viral gene expression and replication.
We then examined the biologic effects of ASP-L in HIV-1
infected cells. We established Molt-4 transformants that
A B
C D


































































































Figure 6 Sub-cellular localization of HIV-1 antisense RNAs. (A) Strand-specific RT-PCR of fractionated samples. An arrow in the upper panel
indicates the region of PCR amplification (R8). Bottom panel, agarose gel electrophoresis of PCR products using samples of HIV-1-infected MAGIC-5A
and chronically infected OM10.1 cells. Cyto, cytoplasmic RNA; Nuc, nuclear RNA; sense, results of sense strand-specific RT-PCR at R8. (B–D) Sub-cellular
distribution of the asRNAs in various HIV-1-infected cells. Relative levels are presented in percentages for MAGIC-5A, OM10.1, and PHA-blast, as well as
simultaneously measured controls. Results of β-actin cytoplasmic RNA and nuclear U3 snoRNA served as controls for fractionation efficiencies.
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the HIV-1 asRNAs (shRNA#1 and shRNA#2, Figure 8A).
To exclude the possible interference against sense strand
RNAs, several mutated nucleotides were introduced into
the passenger strands, which target to HIV-1 sense RNAs.
First, we tested the specificity of these shRNAs using
luciferase reporters having a sense or antisense sequence in
these transformants. The two shRNAs specifically reduced
the levels of luciferase activities of the reporters having
ASP-L sequence, whereas the effects were not significant
for the reporters having sense strand RNA (Figure 8B).
Next, we examined the effects of these shRNAs in HIV-1
replication. The expression levels of the HIV-1 asRNAs in
infected cells were suppressed in these cells compared with
control cells that express a scrambled sequence (Figure 8C).
qRT-PCR of RNA samples from the infected cells demon-
strated significant enhancements of the levels of sense HIV-
1 RNAs in the ASP-L-knockdown cells compared with that
in the control cells (Figure 8D). Virus particle productions
were evaluated by RT-assays using the supernatants of the
infected cells. The RT activities were significantlyenhanced in the samples of stable transformants expres-
sing shRNA#1 and shRNA#2 compared with that of the
control cells (Figure 8E).
Discussion
In the present study, to clarify the natural structure of
HIV-1 asRNAs, we employed a strategy that combines
an artificial overexpression of antisense strand of HIV-1
and characterization of antisense transcripts in infected
cells. The results revealed a natural form of asRNAs of
HIV-1NL4–3 and HIV-1IIIB, ASP-L.
ASP-L appears to be a variant of previously reported ASP
mRNA [8], in that it shares most of the region of the ASP
mRNA, but lacks about 120 to 157 bases in the 5′ region
and extends to the 3′ end by about 499 to 574 bases
(Figure 3A). Previously, two groups reported structural ana-
lyses of ASP mRNAs (Figure 3A); first, Michael et al. iso-
lated a single cDNA for ASP mRNA from a cDNA library
prepared from A3.01 cells infected with HIV-1IIIB [8]. The
transcript started at the nucleotide position 9608 and poly-






























































































































































































Figure 7 ASP-L-mediated inhibition of HIV-1 replication. Results of transient transfection experiments are shown in A to C. (A) HIV-1 RNA
levels at the indicated time points with prior transfection of the ASP-L expression vector, pIRES-RSV-ASP-L, or a vacant vector into MAGIC-5A cells.
The relative expression levels of HIV-1 gag RNA are presented relative to that of HIV-1 gag RNA expressed in mock-transfected cells set as 1.0. (B)
Agarose gel electrophoresis of PCR products of semi-quantitative PCR of genomic DNA samples harvested at the indicated time points. ‘AL’
stands for pIRES-RSV-ASP-L transfected cells. (C) The levels of viral particle production in culture supernatants evaluated by RT assays. MAGIC-5A
cells were transfected with the indicated amounts of the ASP-L expression vector before infection with HIV-1. (D–H) Prolonged inhibition of HIV-1
replication in ASP-L expressing Molt-4 clones. Three clones that stably express ASP-L and three clones transfected with the vacant vector were
used. (D) The levels of virus production evaluated by RT assays. (E and F) HIV-1 RNA levels at 1 day (E) and 4 days (F) post infection (dpi)
measured by qRT-PCR. (G) Agarose gel electrophoresis of PCR products of semi-quantitative PCR of genomic DNA samples at 1 and 4 dpi.. (H)
The relative expression levels of ASP-L that were measured by qRT-PCR.




















































































































Figure 8 Effects of endogenous HIV-1 antisense RNA on HIV-1 expression. (A) Targeted regions of shRNA#1 and #2. Lower panel depicts
secondary structures of expressed shRNAs predicted by m-fold. Lower case letters indicate mutated sites. Boxed sequences are guide strand for
HIV-1 asRNAs. (B) Reporter-based confirmation of strand-specific knockdown. Luciferase reporter plasmids that contain sense HIV-1 sequence or
antisense HIV-1 sequence were transfected into the shRNA-expressing Molt-4 cells. Relative changes of luciferase activities were calculated by
pMIR-sense or AS ASP-L/pMIR-report. The mean ± S.D. of triplicate experiments are shown. Asterisks indicate statistical significance (p< 0.01). (C)
Levels of endogenous HIV-1 asRNAs in HIV-1-infected shRNA expressing cells at 24 h of infection evaluated by strand-specific qRT-PCR at R7.
Asterisks indicate statistical significance (p< 0.009). (D) HIV-1 sense RNA levels at 4 dpi measured by strand-specific qRT-PCR at R7 (env region).
(E) Levels of viral particle production. At the indicated time points, cultured supernatant were collected and subjected to RT-assay. Asterisks
indicate statistical significance.
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http://www.retrovirology.com/content/9/1/38strain, just after the TGA codon. Although a similar
transcript was identified in our overexpression experiments
(transcript IV-ii), this transcript was not identified in our
experiments using HIV-1 infected cells (Figure 3B).
Secondly, Landry et al. reported the structure of another
“ASP mRNA” in 293 T cells transfected with a 5′ LTR-deleted pNL4-3 [11]. The transcript started at various posi-
tions in the 5′ region of the 3′ LTR, and terminated in the
pol region where they found a poly (A) signal at the nucleo-
tide position 4908. This transcript appears to correspond
to the transcript II in our overexpression experiments
(Figure 1C); however, this transcript was detected only in
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sion vector, but not detected in the HIV-1 infected cells in
our experiments (Figure 3B), suggesting that this form of
transcripts may be an artifact in overexpression experi-
ments. As for transcript I, the asRNAs could not be detected
by 3′ RACE method; nevertheless, its expression was sug-
gested by the antisense-specific RT-PCR in the infected
MAGIC-5A (Figure 2B). These results suggested that the
expression level of transcript I is lower than that of ASP-L.
The results of reporter assays and 5′ RACE strongly
support the notion that asRNAs of HIV-1 are transcribed
from 3′ LTR sequence (Figures 3 and 4). Furthermore, con-
sistent with previous reports [8,15,50], our reporter gene
assays suggested that the asRNAs of HIV-1 could be tran-
scribed from 3′ LTR in a TATA − independent and NF-κΒ
− dependent manner (Figure 4D-H). On the other hand,
the absence of TAR sequences in the antisense transcript
may explain the absence of response to Tat (Figure 4C).
These results also imply a possibility that the 5′ LTR may
possess a promoter activity in the antisense direction, which
might contribute to modulate the expression of flanking
cellular genes [6]. In addition to our findings, there remains
a possibility that the antisense promoter activity may also
be influenced by flanking host sequences and the action of
cellular transcription factors, since HIV-1 prefers to inte-
grate into intergenic regions of actively transcribed genes
[6,51]. Also, the transcription of asRNAs might be initiated
within the host flanking sequences in some cases [20].
The results of antisense-specific qRT-PCR analyses indi-
cated that the ratio of expression levels of HIV-1 asRNAs
to those of the sense transcripts varied among the cells
examined (1/100 to 1/2500, Figure 5F). Our result was simi-
lar to that of a previous study in which the authors
estimated 0.9% abundance of HIV-1 asRNAs to the sense
transcriptions [18]. The ratio of expressions was maintained
at various stages of HIV-1 infection in Molt-4 (data not
shown), implying a biological meaning of ASP-L in a life
cycle of HIV-1. Taking our data described in Figures 7 and
8 into consideration, HIV-1 might retain a balanced expres-
sion of sense and antisense genes to avoid acute toxicity. In
addition, the relative expression levels of HIV-1 asRNAs
compared with those of β-actin were confirmed to be
comparable to those of mRNAs of well-known protein en-
coding genes with important functions such as Bcl-2, Cyclin
D1 and IL-2 (data not shown).
To address the biological roles of the asRNA, we per-
formed two experimental studies; first, using cells that
stably overexpress ASP-L, we showed that ASP-L inhibits
HIV-1 gene expression for a prolonged period (Figure 7).
Since ASP-L expression did not affect the levels of HIV-1
DNA and RNA at 24 h post-transfection (Figure 7A, B, E,
and G), ASP-L does not appear to inhibit the early pro-
cesses of infection, such as viral entry and integration into
the genomic DNA of target cells.Next, we performed knockdown assays against the HIV
asRNAs (Figure 8). The results suggested that asRNAs of
HIV-1 including ASP-L might be involved in suppressing
sense strand viral expression. Differences in the efficiency
of viral replication between shRNA#1 and #2 may partly be
attributed to their knockdown abilities (Figure 8B and C),
although precise mechanisms need to be further studied.
Taken collectively, the results suggest that the asRNAs may
be a natural repressor for HIV-1 gene expression, which
may contribute to a self-limited replication.
We demonstrated nuclear localization of ASP-L in the
present study (Figure 6, Additional file 5: Figure S5 and
Additional file 6: Figure S6). Furthermore, our data shown
in Additional file 7: Figure S7 and Additional file 8 suggest
that ASP protein may not be required for the antiviral func-
tion on HIV-1. These observations suggest a function of
ASP-L that is exerted as a functional RNA. One previous
study also raised a possibility that ASP mRNA may act as a
functional RNA [13]. Recent reports demonstrated that the
nuclear mRNA-like noncoding RNAs such as Xist and
HOTAIR have important roles in regulating the sense
strand gene expressions [39,52]. In addition, there is a
possibility that ASP-L could be processed into small inter-
ference RNAs reducing HIV-1 replication [20].
However, considering a previous report that suggested
the presence of antibodies that recognizes ASP protein in
the sera of HIV-1 carriers [9], there remains a possibility
that HIV asRNA may exert its functions both as a
functional RNA and through protein(s) encoded by it. Con-
sidering the function of asRNA of human retroviruses, one
intriguing example would be HBZ of HTLV-1. It has been
reported that bZIP protein encoded by HBZ RNA can
suppress transcription of HTLV-1 sense RNA [22,26], al-
though antibodies that recognize HBZ have not been
reported in sera of HTLV-1-infected individuals. In
addition, some reports have suggested that HBZ RNA itself
can regulate host cellular proliferation [24,25]. Further
studies are required to elucidate detailed functional
mechanisms of ASP-L and its putative translation product
(s).Conclusions
We have identified a 2.6 kb asRNA of HIV-1, a variant of
ASP mRNAs, which is transcribed from the U3 region of
antisense strand of 3′ LTR and terminates in the env
region. The asRNA was expressed in acutely or chronically
infected cells and localized in the nuclei. The expression of
the asRNA led to a prolonged inhibition of HIV-1 replica-
tion, and the knockdown of the ASP-L RNA significantly
enhanced viral replication, suggesting that HIV-1 asRNA
may be a novel factor for the self-limiting replication of
HIV-1. Our finding of a new regulatory asRNA of HIV-1
will improve our understanding of regulatory mechanisms
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for anti-viral therapies.
Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional files.
Methods
Cells and viruses
HEK293T and MAGIC-5A cells [44] were maintained in
DMEM (Dulbecco’s modified Eagle’s medium, Nissui)
supplemented with 10% of heat-inactivated fetal bovine
serum (FBS, GIBCO) and antibiotics. The following cell
lines were maintained with RPMI 1640 medium with 10%
FBS and antibiotics: Molt-4, CEM, HL60, ACH-2 (CEM
cell-derived HIV-1IIIB chronically infected cell line) [47] and
OM10.1 (HL-60 cell-derived HIV-1IIIB chronically infected
cell line) [48]. Human PBMCs were isolated from whole
blood of healthy donors by Ficoll-Paque gradient centrifu-
gation (Amersham Biosciences) and stimulated with 10 ng/
mL of PHA-P (Sigma) for 48 h. The activated PBMCs
(PHA-blasts) were cultured in RPMI 1640 medium supple-
mented with 10% FBS, antibiotics and 20 U/mL of human
recombinant IL-2 (R&D systems). HIV-1 NL4-3 strain was
used for the infection studies. Viral particles were produced
by calcium phosphate transfection of pNL4-3 plasmid in
HEK293Tcells as previously described [53].
Expression vectors
Primers used for generating expression vectors are
described in Additional file 9: Table S1. Primers used for
this study. pME18S-asHIV was used for expression of the
antisense strand of HIV-1NL4–3 (nucleotide position is 653
to 9102). The antisense strand of HIV-1 was obtained by
PCR method with following primers: hiv-pnl-653 and hiv-
pnl-9102, which are prepared based on the nucleotide
sequence of pNL4-3 [53]. The PCR product was cloned
into pGEM-Teasy (Promega) by TA method and sub-
cloned into XbaI/NotI sites of pME18S [54].
The reporter gene plasmids, pGL4-asLTR-1, pGL4-
asLTR-2, pGL4-asLTR-3 and pGL4-asLTR-ΔκB were
generated by inserting PCR amplified fragments with vary-
ing length of the upstream sequence of ASP-L TSS into
SacI (blunted)/XhoI sites of pGL4.10 (Promega). The frag-
ments correspond to the following nucleotide positions of
HIV-1NL4–3: pGL4-asLTR-1, nucleotide position 9425 to
9709; pGL4-asLTR-2, 9425 to 9689; pGL4-asLTR-3, 9425
to 9562; pGL4-asLTR-ΔκB, 9442 to 9709. pGL4-asEnv
was generated by insertion of 200 bp length antisense
fragment of env region that was amplified by p5R and
8514f primers, followed by XbaI/XhoI digestion. pGL4–5′
LTR vector for evaluating the transcriptional activity of
the sense strand LTR was described previously [55]. The
TATA box mutants, pGL4-asLTR-TATA mut1 and pGL4-asLTR-TATA mut2, were prepared by site-directed gene
mutagenesis method [56,57] with primers described in
additional file 9. These vectors were linearized by diges-
tion with PstI or BstXI prior to transfection. pME18S-tat
was used for Tat expression [58,59].
To investigate the effect of ASP-L on HIV-1 replication,
we prepared an ASP-L expression vector, pIRES-RSV-ASP-
L, using an expression vector pIRES-RSV that was derived
from pIRESpuro3 (Clontech) containing RSV promoter.
pIRES-RSV-ASP-L was generated by inserting a proviral
DNA fragment that corresponds to the full-length of ASP-L
at EcoRI/NotI sites. The ASP-L fragment was obtained by
PCR from pNL4-3 with primers 6878f-NotI and 9460r.
Transfections and HIV-1 infections
HEK293T cells (5 × 106) were transfected with 4 μg of
plasmid DNA, pME18S-asHIV or pME18S, as a control,
by Lipofectamine reagent (Invitrogen) according to the
protocol of the manufacturers. After 4 h incubation, the
culture medium was changed and incubated additionally
for 44 h. To obtain the RNA from HIV-1-infected cells,
1.5 × 106 of MAGIC-5A cells were inoculated with
HIVNL4–3 (3 × 10
3 TCID50/50 ml) for 3 days. Total RNA
was isolated by ISOGEN reagent (WAKO, Japan),
followed by poly (A)+ RNA selection by oligo (dT) latex
(Dai-ichi Kagaku Yakuhin, Japan).
For expression of ASP-L gene, 200 ng of pIRES-RSV or
pIRES-RSV-ASP-L were transfected by Lipofectamine 2000
reagent (Invitrogen). After 4 h incubation, culture medium
was changed, followed by inoculation of HIVNL4–3 at 200
TCID50/50 ml. After incubation for 18 h with HIV-1, cells
were washed with DMEM to remove free viruses.
For establishment of T cell lines that stably express
ASP-L, 5 × 106 of Molt-4 cells were transfected with
pIRES-RSV-ASP-L by electroporation, and several clones
were selected by 0.5 μg/mL of Puromycin (Sigma).
Among the Puromycin-resistant clones, three clones
were selected based on the ASP-L expression confirmed
by RT-PCR (3C2, 3F1, and 3G9). These clones were
expanded and inoculated with HIVNL4–3 at MOI = 0.1.
After 24 h of viral attachment, cells were washed by PBS
and cultured in a 6-well plate.
Northern blot analysis
Ten micrograms of total RNA samples were separated by
1% agarose-formaldehyde gel electrophoresis, and trans-
ferred onto a Biodin-A membrane (Pall). Hybridization
was carried out with 7% SDS, 0.2 M Na2HPO4, and 1%
BSA and isotope-labeled DNA probes for overnight at 65°
C, followed by washing with 0.5 × SSC and 0.1% SDS at
65°C. Region specific DNA probes for p1–p5 regions were
generated with PCR (See additional file 9: Table S1. Pri-
mers used for this study). The DNA fragments were TA-
cloned into pGEM-Teasy vector, and the inserted DNA
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The probes were labeled with [α-32P] dCTP by BcaBest la-
belling kit (TAKARA, Japan) according to the manufac-
ture’s protocol.
Strand-specific RT-PCR and quantitative RT-PCR
Primers for RT-PCR are described in the additional file
9. DNaseI-treated RNA samples were reverse-tran-
scribed with Tag-RT-primer at 55°C for 50 min by
SuperScript III reverse transcriptase (Invitrogen). Semi-
quantitative RT-PCR was performed by AccuPrime
DNA polymerase (Invitrogen) with the gene-specific pri-
mer and Tag primer (See also Figure 2A).
For strand-specific quantification, the cDNAs were ana-
lyzed by real-time PCR system (Thermal cycler Dice,
TAKARA). The strand-specific quantitative PCR (qPCR)
was performed by gene-specific primers and SYBRGreen
(TAKARA). Standard curves for strand-specific qRT-PCR
at R7 region were generated by linearized plasmids into
which target strand-specific RT-PCR products were
inserted. Levels of b-actin RNA were measured as internal
controls [55].
3′ and 5′ RACE of antisense RNAs
Both 3′ and 5′ RACE methods were performed with
500 ng poly (A)+ RNA samples according to the manu-
facturer’s protocols (3′- and 5′-Full RACE Core Set,
TAKARA). 1st and 2nd PCRs were performed by
GeneTaq DNA polymerase (WAKO) with region-specific
primers (See additional file 9: Table S1. primers used for
this study).
In silico analyses
Genetyx ver.10 and TFsearch were utilized for the pro-
moter analysis of the HIV-1 asRNAs. For predicting ORFs
and polyadenylation signals, the sequence of ASP-L was
analysed by ORF Finder and HCpolya.
Reporter gene assays
Linearized firefly reporter plasmid and the RSV-
Renilla plasmid were co-transfected into 2 × 105 of
Molt-4 cells with by Lipofectamine2000 reagent. At
24 h post-transfection, cells were harvested and evalu-
ated the promoter activities by measurement of luci-
ferase activities (Dual-Luciferase Reporter Assay
System, Promega). Representative results of quadrupli-
cate or triplicate experiments are presented with the
mean and S.D. Treatment of TNF-α (0–10 ng/ml)
was performed at 12 h post-transfection and the cells
were incubated for an additional 12 h.
Sub-cellular fractionation
Cultured cells were washed with PBS and lysed with lysis
buffer (10 mM Tris–HCl, pH7.5, 10 mM NaCl, 1.5 mMMgCl2, 10 mM Vanadyl Complex, 1% NP-40) on ice for
5 min. After centrifugation in 3,000 rpm for 5 min at 4 Cº,
cytoplasmic supernatant and pelleted nuclei were separated
and resuspended in ISOGEN-LS (WAKO) for RNA extrac-
tion. Relative antisense and sense strand RNA levels were
measured by the strand-specific qRT-PCR method
described above and calculated the enrichment of RNA
levels in each compartment as below. Distribution of inter-
ested RNA was calculated as follows: (% of enrichment in
each fraction) = (level of RNA in nuclear or cytoplasmic
fraction)/(total levels of RNA in nuclear and cytoplasmic
fractions) × 100. The efficiency of the fractionation
procedure was confirmed by testing the distributions of β-
actin cytoplasmic RNA and U3 small nucleolar RNA (U3
snoRNA) [49].
Measurement of virus production
Viral replication was evaluated by measurements of free
virions in the culture media with RT assay [60]. Levels of
intracellular gag and tat RNAs were measured by qRT-
PCR as described previously [55]. Proviral loads were
measured by PCR with p1R and p2F primers (See
additional file 9: Table S1. primers used for this study)
from genomic DNA samples isolated by QIAamp DNA
Blood Mini Kit (Qiagen). Albumin DNA levels were used
as a loading control [55].
Retroviral transduction and strand-specific RNA
interference
Recombinant retroviruses carrying shRNA#1 and #2 were




GAGTAGCACC-3′) into a pSIN-sihU6 vector (TAKARA).
The sequence of scrambled RNA and detailed procedure of
retroviral production were as described previously [55].
After transduction of recombinant viruses and G418 selec-
tion, cells were expanded and inoculated with HIVNL4–3 at
MOI = 0.1. After 24 hours of viral attachment, cells were
washed with PBS and then cultured in a 12-well culture
plate.
To confirm the strand-specific knockdown by shRNAs,
the cells were transfected with pMIR-REPORT (empty
plasmid, Ambion), pMIR-sense ASP-L or pMIR-AS ASP-
L, respectively. These reporters include sense or antisense
HIV-1 sequence in the 3′UTR of luciferase gene.
Additional files
Additional file 1: Figure S1. Determination of transcript III-iii. (A)
Results of 3' RACE. Top panel summarizes the results. Agarose gel
electrophoresis of 3' RACE PCR products is shown in Figure 3B. The
results of the sequence analyses are shown in the bottom panel.
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http://www.retrovirology.com/content/9/1/38Bars and arrows indicate the identified termination sites. The bold arrow
shows the major transcript. The upper case letters and arrows in the
sequence indicate the termination sites of transcript III-iii. (B) Termination
positions of transcript III-iii described in the context of pME18S-asHIV.
Additional file 2: Figure S2. Detection of spliced HIV-1 antisense
RNAs. (A) A map of primer pairs at R11 and R12. (B-C) Results of agarose
gel electrophoresis of antisense-specific RT-PCR products at R11 (B) and R12
(C). Expected PCR products derived from spliced transcripts were
approximately 2 kb (B) and 400 bp (C), respectively (indicated by asterisks in
lane 2), which are shorter than that of full-length (6 kb at R11 and 5 kb at
R12). Experiments were performed using total RNAs from HEK293T with
pME-18 S-asHIV (293 T-asHIV) (left panel) and HIV-1-infected MAGIC-5A
(right panel). Lane 1 and 7, cells transfected with a mock vector or no
infection control; Lane 2 and 8, cells with pME18S-asHIV or HIV-1 infection;
Lane 3 and 9, no RTase control; Lane 4 and 10, no RT primer control; Lane 5
and 11, PCR products with conventional primer pairs with cDNA samples
synthesized by random primers; Lane 6 and 12, positive control (amplified
from pME18S-asHIV plasmid DNA, or from pNL4-3 plasmid DNA); M, 100 bp
marker; λ, λ/Hind III marker.
Additional file 3: Figure S3. HIV-1 antisense RNA pattern in infected
cells. MAGIC-5A cells were infected with HIV-1NL4–3 and then analyzed
antisense RNAs by antisense-specific RT-PCR at regions R9 (for original ASP
mRNA) and R10 (for ASP-L). Representative results (n = 4) were shown. ASP-L
was mainly detected. Lanes 1–6 are the same as in Figure 2B.
Additional file 4: Figure S4. Transcriptional activation of HIV-1
antisense RNAs by TNF-α treatment. ACH-2 was treated with TNF-α
(10 ng/mL) for 24 h. Total RNAs were extracted and analyzed by strand-
specific qRT-PCR at R7. The asterisks denote statistical significance relative to
the untreated control (p< 0.02).
Additional file 5: Figure S5. Sub-cellular localization of HIV-1
antisense RNAs in the HIV-1 infected T cell lines. Results of subcellular
localization analysis of T-cell lines. RNA samples were prepared from
cytoplasmic and nuclear fractions of ACH-2 cells and HIV-1NL4–3-infected
Molt-4 cells as described in the text.
Additional file 6: Figure S6. Sub-cellular localization of ASP-L in the
Molt-4 cells stably expressing ASP-L. RNA samples were prepared from
cytoplasmic and nuclear fractions of Clone 3G9 cells. Results of the
quantitative measurement of RT-PCR at R7 are presented from cDNAs
synthesized with random primers. Fractionation efficiencies were confirmed
by measuring the levels of β-actin cytoplasmic RNA and nuclear U3 snoRNA.
Additional file 7: Figure S7. Inhibitory effects of full-length ASP-L RNA
on HIV-1 replication. (A) ASP-L mutants. ASP-L3′ is a portion of ASP-L
bearing the ASP-coding region. ASP-LΔATG contains an A to T mutation at
the start codon of ASP. ASP-LC-stop contains a C to A mutation at the
seventh codon of ASP to convert Cysteine into a stop codon. Detailed
sequences are provided in the right panels. Upper cases in the nucleotide
sequences show the mutated sites. (B–C) Effects of ASP on HIV-1
replication. (B) Expression levels of ASP-L3′ measured by qRT-PCR at R7.
mock, Clone 2B3 with the empty vector; wt, Clone 3C2 stably expressing
wild type ASP-L (Figure 7D–G); c9F and c5D, established Molt-4 clones that
stably express ASP-L3′; Molt4, uninfected Molt-4 cells; Molt4-HIV, HIV-1NL4–3
infected Molt-4. (C) HIV-1 RNA levels at 4 days post HIV-1NL4–3 infection. HIV-
1 RNA levels were evaluated by qRT-PCR with gag and tat genes (mean ± S.
D). (D) Effects of ASP-L RNA on HIV-1 replication. 50 ng or 200 ng of pIRES-
RSV-ASP-LΔATG (dATG) or pIRES-RSV-ASP-LC-stop (C-stop) was transfected into
MAGIC-5A, followed by HIV-1NL4–3 infection. Viral production levels were
evaluated by RT assays with the supernatants at 72 h post-transfection. (E)
HIV-1 gag RNA levels at 48 h post-transfection measured by qRT-PCR.’mock’
stands for MAGIC-5A with empty vector. ‘wt’ stands for MAGIC-5A with
pIRES-RSV-ASP-L.
Additional file 8: Supplemental materials and methods. Supplemental
materials and methods for expression vectors in Figure S7 are described.
Additional file 9: Table S1. Primers used for this study.
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